A 24-month, Prospective, Non-interventional Study to Describe the Long Term, Real-Life Use of BOTOX® for the Symptomatic Treatment of Adults With Chronic Migraine, Measuring Healthcare Resource Utilization, and Patient Reported Outcomes Observed in Practice
Phase of Trial: Phase IV
Latest Information Update: 21 Nov 2018
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms REPOSE
- Sponsors Allergan
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
- 29 Nov 2017 According to an Allergan media release, data from the study will be presented at the 11th European Headache Federation (EHF) Congress 2017.
- 10 Sep 2017 Results assessing long term use of Onabotulinumtoxin A (BOTOX) as prescribed by the physician for headache prophylaxis in adults with chronic migraine, were presented at the 2017 International Headache Society.